All the news Showing 10 of 119 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Curing hepatitis C reduces the risk of diabetes & kidney failure in people with HIV/HCV co-infection Keith Alcorn / 01 February 2017 Curing hepatitis C infection substantially reduces the risk of developing type 2 diabetes in people with HIV/hepatitis C virus (HCV) co-infection, but does not reduce the risk of cardiovascular disease, ... Curing hepatitis C reduces liver-related complications and death Liz Highleyman / 23 January 2017 People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to people who were not successfully treated, according to research presented at the 2016 ... US research identifies information priorities for people who are candidates for HCV therapy Michael Carter / 14 December 2016 People with hepatitis C virus (HCV) who are candidates for therapy with new all-oral regimens want information on the potential harms and benefits, details of treatment regimens and also basic information on HCV-related ... Generic sofosbuvir-based therapy under performs in real-world setting, but is use of suboptimal regimens the reason? Michael Carter / 09 December 2016 Generic sofosbuvir-based combinations may not perform as well as therapy based on branded sofosbuvir-containing regimens, according to result of a study conducted in Qatar and presented to the recent 2016 AASLD Liver Meeting. ... Real-world studies show 8-week sofosbuvir/ledipasvir course just as effective as 12-week course for genotype 1 patients without cirrhosis Keith Alcorn / 02 December 2016 An 8-week course of treatment with sofosbuvir/ledipasvir is just as effective as a 12-week course of treatment in people without cirrhosis, including those with HIV/hepatitis C virus (HCV) co-infection, and could significantly reduce ... Real-world responses to HCV treatment among US veterans match best clinical trial results Keith Alcorn / 14 November 2016 Direct-acting antiviral (DAA) treatment is curing people of hepatitis C infection in clinics at similar rates to those seen in clinical trials, and there don’t seem to be major differences between drug regimens, ... AbbVie 3D regimen taken for 8 weeks cures almost all HCV genotype 1b patients without cirrhosis Liz Highleyman / 06 October 2016 AbbVie’s paritaprevir-based ‘3D’ regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat patients with hepatitis C virus (HCV) genotype 1b who did not have cirrhosis, ... 100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks Liz Highleyman / 05 October 2016 A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with previously untreated genotype 1 hepatitis ... People with HCV attaining SVR continue to have increased mortality risk but this is due to alcohol and drug use Michael Carter / 03 October 2016 Mortality rates among people with hepatitis C virus (HCV) who attain a sustained virological response after HCV treatment are approximately twice as high as those expected in the general population, Scottish investigators report ... Risk of reinfection is a concern after successful hepatitis C treatment Liz Highleyman / 28 September 2016 People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) – achieving cure rates similar to those of the population as a whole – but some people are reinfected ... ← Prev1...34567...12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive